Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.

IF 3.6 3区生物学 Q2 MYCOLOGY

Mycopathologia Pub Date : 2025-07-04 DOI:10.1007/s11046-025-00969-z

Isabela Lima Miranda, Nalu Teixeira Aguiar Peres, Rafael Wesley Bastos, Luana Rossato, Florent Morio, Daniel Assis Santos

{"title":"Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.","authors":"Isabela Lima Miranda, Nalu Teixeira Aguiar Peres, Rafael Wesley Bastos, Luana Rossato, Florent Morio, Daniel Assis Santos","doi":"10.1007/s11046-025-00969-z","DOIUrl":null,"url":null,"abstract":"<p><p>Trichosporon spp. are ubiquitous environmental and emerging opportunistic fungi that can be part of the normal microbiota of the skin, vagina, and gastrointestinal tract in humans and other animals. In a state of microbiota imbalance, both immunocompromised and non-immunocompromised patients are susceptible to trichosporonosis, which can present as either superficial infections, such as White Piedra, or deep-seated infections, such as fungemia. Due to intrinsic resistance or limited efficacy reported with fluconazole, polyenes, echinocandins, and flucytosine, voriconazole is currently recommended in clinical guidelines. Biofilm formation and the overexpression of efflux pumps may contribute to this limited efficacy, but other resistance mechanisms have also been reported. The high antifungal resistance levels present in this genus highlight the urgent need for new therapeutic approaches and a better understanding of Trichosporon pathogenesis and the molecular mechanisms underlying this resistance. In this review, we discuss antifungal resistance and the mechanisms of this resistance in Trichosporon spp., addressing key points that require further investigation.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"190 4","pages":"59"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-025-00969-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Trichosporon spp. are ubiquitous environmental and emerging opportunistic fungi that can be part of the normal microbiota of the skin, vagina, and gastrointestinal tract in humans and other animals. In a state of microbiota imbalance, both immunocompromised and non-immunocompromised patients are susceptible to trichosporonosis, which can present as either superficial infections, such as White Piedra, or deep-seated infections, such as fungemia. Due to intrinsic resistance or limited efficacy reported with fluconazole, polyenes, echinocandins, and flucytosine, voriconazole is currently recommended in clinical guidelines. Biofilm formation and the overexpression of efflux pumps may contribute to this limited efficacy, but other resistance mechanisms have also been reported. The high antifungal resistance levels present in this genus highlight the urgent need for new therapeutic approaches and a better understanding of Trichosporon pathogenesis and the molecular mechanisms underlying this resistance. In this review, we discuss antifungal resistance and the mechanisms of this resistance in Trichosporon spp., addressing key points that require further investigation.

查看原文本刊更多论文

毛磷体和抗真菌耐药性：当前的知识和差距。

毛丝虫病是普遍存在的环境和新兴的机会性真菌，可以是人类和其他动物的皮肤，阴道和胃肠道的正常微生物群的一部分。在微生物群失衡的状态下，免疫功能低下和非免疫功能低下的患者都易患三磷菌病，其表现为浅表感染，如白斑病，或深层感染，如真菌血症。由于氟康唑、多烯类、棘白菌素和氟胞嘧啶的固有耐药性或有限疗效，伏立康唑目前被推荐在临床指南中。生物膜的形成和外排泵的过度表达可能导致这种有限的疗效，但其他的耐药机制也有报道。该属的高抗真菌水平突出了迫切需要新的治疗方法和更好地了解毛霉的发病机制和这种耐药的分子机制。本文就毛孢霉的抗真菌耐药性及其机制进行了综述，并指出了有待进一步研究的重点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mycopathologia 生物-真菌学

CiteScore

6.80

自引率

3.60%

发文量

审稿时长

3 months

期刊介绍： Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.